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Abstract. 
Mucoepidermoid carcinoma is considered to be one of the salivary gland-type cancers, 
which seldom originate from the lung. Herein, we report a 69-year-old female with primary 
pulmonary high-grade mucoepidermoid carcinoma. The disease progressed rapidly and reached 
an unresectable status. We treated the patient with bi-weekly doses of docetaxel and the clinical 
response allowed for the disease to become more stable. The patient survived for only six 
months from the onset of the symptoms. The case demonstrated that single use of docetaxel 
would appear to be a treatment option for mucoepidermoid carcinoma of the lung. 
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病例報告  
Docetaxel 使用於肺部黏液類上皮癌 
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中文摘要 
  黏液類上皮癌是一種好發於唾液腺的癌症，但極少源自於肺部且對於化學治療的效
果都不盡理想。於此，我們報告了一位 69 歲女性罹患原發性肺部黏液類上皮癌。其疾病
的進展相當迅速，而且很快就發展成為無法切除的腫瘤。在這個病人身上，我們使用了
每兩周注射一次的 docetaxel 化療藥，病人的病情得到初步控制。這個病例的反應告訴我
們 docetaxel 在原發性肺部黏液類上皮癌上，也許可以作為治療選項之一。 
 
關鍵字: 肺部黏液類上皮癌、docetaxel 
 
INTRODUCTION 
Mucoepidermoid carcinoma (MEC) is an uncom-
mon tumor of the lung that accounts for 0.1 to 0.2% of 
all pulmonary cancers [1]. Primary pulmonary MEC 
often appears as lobulated and intraluminal nodules 
with distinct margins, and is primarily located in the 
segmental bronchi as opposed to the trachea or main 
bronchi [2]. 
MEC can develop at almost any age, ranging from 
3 to 78 years, but most patients are generally young 
adults [3]. Most MECs are benign with an indolent 
clinical course, but some presented with malignant 
behaviors involving multiple metastasis and visceral 
invasion. Currently, there is no consensus regarding 
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optimal treatments for malignant or high-grade MECs. 
Herein, we report a case of primary pulmonary MEC 
receiving systemic chemotherapy with docetaxel.  
 
CASE REPORT 
A 69-year-old female with a history of diabetes 
mellitus was followed-up from the cardiology outpa-
tient department. In August 2013, she presented with 
right-sided chest pain and dry cough for one month. In 
addition, she also suffered from weight loss of more 
than 10 kilogram over a period of three months. A 
chest X-ray revealed a mass lesion over the right low-
er lung. Then she was transferred to the department of 
thoracic surgery. The patient underwent a computed 
tomography (CT) scan in September 2013, which 
showed a bronchogenic tumor and obstructive pneu-
monia at the right lower lobe with pleural invasion 
and right hilar lymphadenopathy (Figure 1A,1B). Oth-
er exams including magnetic resonance imaging of the 
brain, abdominal sonography, and Tc-99m whole body 
bone scan revealed no evidence of distal metastasis. 
This patient underwent video-assisted thoraco-
scopic wedge resection of the right lower lobe. The 
pathology revealed cancer cells with pleomorphic nu-
clei, prominent nucleoli, and moderate cytoplasm ar-
ranged in sheets or a nest pattern with desmoplastic 
stroma. The immunohistochemical stains were shown 
to be positive for CK7, CK5/6, mucin, and p40, but 
negative for TTF-1, synaptophysin, and CD56 (Figure 
2). Review of the available data and diagnostic infor-
mation indicated the patient had a primary pulmonary 
mucoepidermoid carcinoma, cT3N1M0, stage IIIA.  
However, an episode of acute cerebral infarction and 
sepsis occurred after operation. Subsequent systemic 
chemotherapy was postponed due to poor performance 
status (Eastern Cooperative Oncology Group (ECOG): 
3). The patient received supportive care and was fol-
lowed-up in our hematology department.  
In November 2013, the patient was evaluated for 
further chemotherapy. Her performance was slightly 
improved (ECOG: 2). A follow-up CT scan revealed 
multiple nodules over the bilateral lung with an inva-
sion of the mediastinum and right lateral chest wall, 
and right hilar and mediastinal lymphadenopathies 
(Figure 1C,1D).The disease worsened and progressed 
to cT4N2M0, stage IIIB.  
She received palliative chemotherapy with docet-
axel, 40 mg/m2 every two weeks, starting in Decem-
ber 2013. A CT scan in January 2014 (8 weeks after 
treatment) revealed mild shrinkage of the right lower 
lung tumors (Figure 1E,1F), and we considered its ef-
ficacy as ”stable disease” according to RECIST guide-
lines (version 1.1). During her chemotherapy treat-
ment, the patient didn’t experience febrile neutropenia 
or sepsis. Nevertheless, the patient requested to dis-
continue chemotherapy due to general malaise with 
deterioration of performance status. The patient then 
died from cardiac arrest related to a choking episode 
in February 2014. 
 
DISCUSSION 
MEC is considered to be one of the salivary 
gland-type cancers, which are rare lung neoplasms 
including MEC, adenoid cystic carcinoma (ACC), and 
epithelial-myoepithelial carcinoma (EMC) according 
to the World Health Organization (WHO) classifica-
tion [4]. Salivary gland-type lung cancers are a group 
of low-aggressive entities with a higher likelihood of 
recurrence and metastasis [4]. These tumors are slow 
growing and arise from the submucosal glands of the 
bronchial tree [5].  
MEC is classified into two groups according to 
its pathological features and clinical behaviors. 
Low-grade tumors are composed mostly of cysts, are 
confined to the bronchial wall, and it is unusual for 
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Figure 1. A CT scan of the chest in September 2013 (A and B) showed a bronchogenic tumor and obstructive 
pneumonia at the right lower lobe with pleural invasion and right hilar lymphadenopathy (maximal 
diameter: 14.37 cm). In November 2013 (C and D), multiple nodules were progressively enlarged over 
the bilateral lung with an invasion of mediastinum and right lateral chest wall, and right hilar and me-
diastinal lymphadenopathies (maximal diameter: 15.98 cm). The follow-up CT scan after treatment in 
January 2014 revealed mild shrinkage of the right lower lung tumors (maximal diameter: 14.98 cm) 
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Figure 2. The pathology revealed cancer 
cells with pleomorphic nuclei, 
prominent nucleoli, and moder-
ate cytoplasm arranged in sheets 
or a nest pattern with desmo-
plastic stroma (A,B) with posi-
tive for CK7(C), CK5/6(D), mu-
cin (E), and p40(F), but negative 
for TTF-1(G) in immunohisto-
chemical stains 
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metastasis to progress to regional lymph nodes [5-8]. 
High-grade tumors display sheets or nests of mu-
cus-secreting, squamous and intermediate cells mixed 
with mitotic activity and necrosis, and they also ex-
hibit aggressive patterns with invasion to regional 
lymph nodes, interstitium, or lung parenchyma [5-7]. 
Heitmiller et al. reported one series with 18 pulmo-
nary MECs, where 15 patients were low-grade type 
and 3 patients were high-grade type tumors. All 15 
patients with low-grade tumor were alive without re-
currence at a mean follow-up of 4.7 years, and all pa-
tients with high-grade tumors were deceased within 16 
months [7].  
Although pulmonary MEC is rare, it shares a sim-
ilar pathology to the relatively more common salivary 
MEC [3]. MEC of the salivary gland and lung also 
share similar reciprocal translocation involving chro-
mosome 1q32, 5p15, 7q22, and 15q22 [9]. Recurring 
t(11;19) translocation with an associated CRTC1- 
MAML2 fusion oncogene is present in 38-81% of 
such tumors [10]. This translocation may exist in all 
grades of MEC [11], and fusion protein is associated 
with the regulation of cell-cycle pathways, activation 
of EGFR signaling, and increased expression of am-
phiregulin (EGFR ligand) [12].  
Surgery consisting of radical resection of the pri-
mary tumor is still the current treatment of choice, 
especially for low-grade tumors that are at an early 
stage of the disease [13]. The definitive benefits of 
chemotherapy are lacking at this time for MEC. 
Chemotherapy has been used in locally advanced or 
metastatic mucoepidermoid carcinoma of the salivary 
glands [14,15]. The response rates vary from 10% to 
46% [14-17]. Combined therapy with anthracycline 
and platinum agents would appear to be more promis-
ing then the use of single agents [16,17]. Taxane 
agents have been shown to have an impressive an-
ti-tumor activity especially in squamous cell carcino-
ma of the head and neck cancers with a response rate 
of 32% (95% confidence interval 17-47%), median 
duration of response of 4.5 months (range, 2-20 
months), a median survival of 9.2 months, and a 
1-year survival rate of 33% [18,19]. Since such a pos-
itive response has been observed, taxane agents have 
been used in cases of MEC of the salivary glands. One 
report showed a surprising response to docetaxel in 
four cases that had MEC of the salivary glands, but 
showed the patients remained stable for at least 18 
months after six cycles of chemotherapy [20,21]. An-
other report showed a partial response lasting 5 and 12 
months to carboplatin and paclitaxel in 2 of 14 pa-
tients with recurrent MEC of the salivary glands [22]. 
Our case was treated with the single use of docetaxel 
(40 mg/m2 every two weeks) chemotherapy for the 
aged patient that suffered from a poor performance 
status, anti-tumor activity of docetaxel, and the ac-
ceptable safety profile. The response was favorable 
with the patient continuing to have stable disease for 
at least 2 months. Therefore, single use of taxane ap-
pears to be an alternative treatment to consider for 
MEC of the lung. 
Recently published reports put an emphasis on 
epidermal growth factor receptor (EGFR) mutation of 
the tumor. Although a definite association between 
mutation and MEC is not clearly established at this 
time, mutations of EGFR including L861Q mutation 
in exon 21 and exon 19 deletion have been found in 
some patients [23]. Some reports demonstrated that 
patients lacking a sensitizing EGFR mutation revealed 
clinical response of pulmonary MEC to tyrosine ki-
nase inhibitors of EGFR [24,25].  
Here, we report on a case of primary pulmonary 
MEC treated with single use docetaxel chemotherapy. 
Although we discontinued treatment due to the pa-
tient’s senescence and weakness, the patient continued 
to have stable disease for at least 2 months without 
chemotherapy-associated febrile neutropenia. Further 
studies are necessary to investigate the role of sys-
temic chemotherapy in high-grade MEC. 
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